TLR2 and Parkinson disease: In addition, downregulation of TLR2 and TLR8 by 2 months (−1.77‐fold, p = 0.0348; and −1.99‐fold, p = 3.09 × 10−6, respectively) and 6 months (−1.66‐fold, p = 1.06 × 10−6; and −2.598‐fold, p = 1.66 × 10−6, respectively) of treatment supports an anti‐inflammatory neuroprotective signature for sargramostim therapy in PD.